People

Sylvain Celanire

augustinetx.com

Sylvain Celanire was the Chief Executive Officer of Augustine Therapeutics in its2021 and2024 published financing and research announcements. He led the company as it advanced selective HDAC6 inhibitors for peripheral neuropathies and neuromuscular disease. Augustine appointed Gerhard Koenig as CEO in January2025; Celanire’s issuer affiliation here is historical, and no current executive position is asserted.